Type 1 Plasminogen Deficiency With Pulmonary Involvement: Novel Treatment and Novel Mutation

J Pediatr Hematol Oncol. 2021 May 1;43(4):e558-e560. doi: 10.1097/MPH.0000000000001951.

Abstract

Type 1 plasminogen deficiency is a rare genetic disorder. Type 1 plasminogen deficiency is characterized by fibrin-rich pseudomembrane formation on mucosal surfaces, particularly the conjunctiva. Tracheobronchial tree involvement is a less common reported manifestation of type 1 plasminogen deficiency. Pseudomembranes in the tracheobronchial tree may result in respiratory compromise and ultimately fail if not recognized and treated. Currently, there is no specific replacement therapy approved for the treatment of congenital plasminogen deficiency. In the present paper, we report that type 1 plasminogen deficiency with novel frameshift mutation and pulmonary involvement was treated initially with systemic fresh frozen plasma followed by pulmonary lavage with fresh frozen plasma and tissue plasminogen activator.

Publication types

  • Case Reports

MeSH terms

  • Blood Component Transfusion
  • Conjunctivitis / genetics*
  • Conjunctivitis / pathology
  • Conjunctivitis / therapy
  • Frameshift Mutation*
  • Humans
  • Infant
  • Lung / pathology
  • Male
  • Plasminogen / deficiency*
  • Plasminogen / genetics*
  • Skin Diseases, Genetic / genetics*
  • Skin Diseases, Genetic / pathology
  • Skin Diseases, Genetic / therapy
  • Tissue Plasminogen Activator / therapeutic use

Substances

  • Plasminogen
  • Tissue Plasminogen Activator

Supplementary concepts

  • Plasminogen Deficiency, Type I